TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16530503
Drug: Peginterferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alfa‐2b monotherapy (1.5 microg/kg per week) started at week 8
Study: 16530503
Drug: Peginterferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alfa‐2b monotherapy (1.5 microg/kg per week) started at week 12
Study: 9301631
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg atorvastatin at night
Study: 30257125
Drug: Zinc‐/copper‐containing welding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc‐/copper‐containing welding fumes (2.5 mg/m3)
Study: 26562003
Drug: Head Massage
Normalized name: Drive Shwrhead Massager HndHld
Approvals — FDA: no, EMA: no, PMDA: no
Description: Head Massage Therapy (HMT)
Study: 22332874
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro insulin stimulation in infants with maternal T1D
Study: 18538113
Drug: ZyrtecA (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZyrtecA (reference formulation)
Study: 18538113
Drug: RyvelA (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: RyvelA (test formulation)
Study: 8751234
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily for 7 days
Study: 11083409
Drug: Alpha-blocker treatment
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-blocker treatment
Study: 6414271
Drug: Amipaque, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amipaque, 300 mg l/ml
Study: 31022446
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg hydrocortisone (intervention group)
Study: 21919922
Drug: Prazosin (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (16 mg daily)
Study: 15039349
Drug: Vaccinated birds
Normalized name: Bird pepper
DrugBank: Bird pepper (DB14262)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinated birds (DNA vaccine plasmid encoding the circumsporozoite protein of P. relictum)
Study: 9757855
Drug: Low-fat dairy
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat dairy products containing up to 1200 mg/d of calcium
Study: 26506383
Drug: Sarcosine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarcosine (2 g daily for six months)
Study: 21383836
Drug: Descending piano
Normalized name: Defend II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Descending piano melody exposure during the 35th, 36th, and 37th weeks of gestation, twice daily for 3 weeks.
Study: 9541360
Drug: Potassium iodate
Normalized name: Potassium Iodate
DrugBank: Potassium iodate (DB15923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium iodate added to irrigation water (10-80 microg/l) for 2-4 weeks
Study: 2880214
Drug: Intravenous glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glycerol (500 ml of a 10% solution in physiological saline)
Study: 2880214
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline (500 ml administered intravenously)
Study: 10356602
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 1500 mg daily
Study: 6670591
Drug: Iohexol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iohexol (10 to 15 ml, 180 mg I/ml)
Study: 12865603
Drug: High-dose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose heparin
Study: 10551687
Drug: Standard-dose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose heparin
Study: 20410427
Drug: Threshold value
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Threshold value of 52 mL/m(2) for cortical renal volume-resistive index product
Study: 17234558
Drug: MMX mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMX mesalamine 2.4 g/day given twice daily
Study: 17234558
Drug: MMX mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMX mesalamine 4.8 g/day given once daily
Study: 10783996
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg pantoprazole
Study: 31096515
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg esomeprazole
Study: 26729950
Drug: Adjunct statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunct statin therapy with DMARDs
Study: 24410484
Drug: Canrenone 25
Normalized name: canrenone
DrugBank: Canrenone (DB12221)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canrenone 25 mg
Study: 25125488
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 12.5 mg
Study: 17710010
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine (n=18)
Study: 17710010
Drug: Patients (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients (combined treatment)
Study: 16162697
Drug: Lansoprazole, 30
Normalized name: Lansoprazole, 30 mg oral tablet, disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole, 30 mg bid for 24 weeks
Study: 10455094
Drug: Mivazerol (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivazerol (oral administration over a two week period)
Study: 2690660
Drug: Alcohol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (1.0 ml of 100% alcohol/kg body weight)
Study: 30427588
Drug: Ertugliflozin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin monotherapy (15 mg)
Study: 30427588
Drug: Ertugliflozin/Sitagliptin FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin/Sitagliptin FDC (15-100 mg)
Study: 30427588
Drug: Ertugliflozin/Metformin FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin/Metformin FDC (7.5-1000 mg)
Study: 30427588
Drug: Ertugliflozin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin monotherapy and FDCs
Study: 30427588
Drug: Ertugliflozin/Metformin FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin/Metformin FDC
Study: 26431906
Drug: ARA290 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARA290 (2 mg)
Study: 24267254
Drug: Triple-therapy with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-therapy with simvastatin (40 mg daily), extended-release niacin (1500 mg daily), and ezetimibe (10 mg daily)
Study: 24267254
Drug: Mono-therapy with
Normalized name: tiotropium bromide mono
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mono-therapy with simvastatin (40 mg daily)
Study: 19723123
Drug: Tonabersat, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonabersat, a gap-junction modulator, well tolerated, no cardiovascular effects, pharmacokinetic profile suggests usefulness in migraine prophylaxis.
Study: 19723123
Drug: Antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drugs and beta-blockers, commonly used preventive therapies, mechanisms of action unknown.
Study: 15217131
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of 15 ml 2% Lidocaïne gel
Study: 15217131
Drug: Lidocaïne periprostatic
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaïne periprostatic infiltration (10 ml of 1% Lidocaïne in two injections)
Study: 7863993
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 and 100 mg/day)
Study: 1645332
Drug: BV-araU 30
Normalized name: Bifidobacterium longum bv. infantis whole
DrugBank: Bifidobacterium longum infantis (DB14222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BV-araU 30 mg/day
Study: 19787809
Drug: Boceprevir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boceprevir (400 mg twice or three times daily for 14 days)
Study: 11575414
Drug: Intrathecal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal midazolam with bupivacaine (BM1: 1 ml of 0.5% bupivacaine plus 0.2 ml of 0.5% midazolam)
Study: 11575414
Drug: Intrathecal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal midazolam with bupivacaine (BM2: 1 ml of 0.5% bupivacaine plus 0.4 ml of 0.5% midazolam)
Study: 11575414
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (1 ml of 0.5% heavy bupivacaine plus 0.2 ml of 0.9% saline)
Study: 9849260
Drug: Three noncontact
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three noncontact Therapeutic Touch treatments (15 to 20 minutes duration)
Study: 25781525
Drug: Oral Contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Contraceptive Pills (OCP)
Study: 30214821
Drug: Prednisolone plus
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone plus antibiotics
Study: 788768
Drug: Antibiotic alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic alone
Study: 26289950
Drug: Pharmacist-acquired medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-acquired medication history (MH) during admission to ED
Study: 19135415
Drug: Palonosetron (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron (0.75 mg) with dexamethasone
Study: 14734594
Drug: Memantine (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (starting dose 5 mg/d, increased to 20 mg/d, n = 203)
Study: 12575607
Drug: Nitrolingual injection
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrolingual injection 15 mg in 5% glucose solution 500 ml for intravenous dripping, once a day for 2 weeks
Study: 8163713
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug with forced titration scheme
Study: 8163713
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug (three arms with different maximum allowable doses)
Study: 30479020
Drug: Dose-matched attention
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose-matched attention control
Study: 31635538
Drug: Present-centered therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Present-centered therapies for PTSD
Study: 27187320
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg E + 15 mg P (Group A)
Study: 27187320
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg E + 20 mg P (Group B)
Study: 27187320
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg E + 30 mg P (Group C)
Study: 20353582
Drug: All modes
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All modes of administration
Study: 16891634
Drug: 108 mg
Normalized name: camphor 108 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 108 mg hyperbaric articaine hydrochloride (A108)
Study: 1740582
Drug: Ragweed immunotherapy
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ragweed immunotherapy (IT)
Study: 25449826
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration (WBV) therapy
Study: 20890791
Drug: Neodolpasse(®) Infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neodolpasse(®) Infusion Solution
Study: 15084760
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate depot 3.75 mg once a month for 3 months and cyproterone acetate 300 mg once a week for 3 weeks (group A)
Study: 9757854
Drug: Nafarelin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin alone (200 microg intranasally twice daily)
Study: 9757854
Drug: Nafarelin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin plus human parathyroid hormone‐(1‐34) (hPTH‐[1‐34]) (40 microg subcutaneously daily)
Study: 8151606
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium (80 mmol/day) with fish oil (5 g of omega-3 fatty acids per day)
Study: 26894151
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1 μg/kg + bupivacaine local infiltration + Dexemedetomidine infusion (Loading 0.5 μg/kg, Maintenance 0.2μg/kg/hr)
Study: 26894151
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1 μg/kg + bupivacaine local infiltration
Study: 24205786
Drug: Complementary therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary therapy (CT)
Study: 2309645
Drug: Mackerel paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mackerel paste (135 g daily)
Study: 27545497
Drug: TDF 300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF 300mg once daily
Study: 27545497
Drug: FTC 200mg
Normalized name: (-)-FTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTC 200mg and TDF 300mg once daily
Study: 7547078
Drug: Recombinant IFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant IFN alpha‐2b (3 x 10(6) IU 3 times weekly)
Study: 2675757
Drug: Norfloxacin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (800 mg single dose)
Study: 26650491
Drug: 1.8 mL
Normalized name: insulin pump syringe, 1.8 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mL of 2% lidocaine for inferior alveolar nerve block (IANB)
Study: 16413328
Drug: Alfuzosin 10
Normalized name: Alfuzosin 10mg Oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 10 mg once daily for 4 weeks
Study: 10813541
Drug: 7 L
Normalized name: WT-1 427 long
DrugBank: WT-1 427 long (DB17354)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 L leukapheresis
Study: 10813541
Drug: 10 L
Normalized name: PEG-10 LANOLIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 L leukapheresis
Study: 8856576
Drug: Amino acids
Normalized name: Amino acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acids (L-alanine, L-glutamine, L-phenylalanine, L-proline)
Study: 1478771
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment for 36 weeks followed by active treatment for 30 weeks (crossover group)
Study: 6139346
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg zetidoline
Study: 29332068
Drug: Oral steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroids (1 mg/kg/day of prednisolone for 6 days prior to surgery)
Study: 3265156
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no steroids)
Study: 21719866
Drug: HQ system
Approvals — FDA: no, EMA: no, PMDA: no
Description: HQ system (cleanser, toner, proprietary 4% hydroquinone, exfoliant, and sunscreen) plus 0.05% tretinoin cream
Study: 10463317
Drug: Naltrexone 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 25 mg
Study: 2167107
Drug: Naltrexone 0
Normalized name: MORPHINE 20MG/NALTREXONE 0.8MG SA CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 0 mg (placebo)
Study: 11862370
Drug: Naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 50 mg
Study: 11557167
Drug: Naltrexone 100
Normalized name: naltrexone 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 100 mg
Study: 7021070
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg flurbiprofen daily
Study: 7021070
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between flurbiprofen and enteric-coated aspirin
Study: 7021070
Drug: Side effects
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Side effects reported for aspirin
Study: 31563881
Drug: Dexamethasone 4
Normalized name: dexamethasone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 4 mg/mL
Study: 26413530
Drug: ICP-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICP-guided therapy (ICP < 20 mmHg and CPP > 60 mmHg)
Study: 15097262
Drug: Dorzolamide/Timolol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide/Timolol fixed combination
Study: 9270086
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg felodipine daily for 3 months
Study: 9270086
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg felodipine daily for 3 months
Study: 9270086
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg felodipine
Study: 8665996
Drug: Felodipine treatment
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine treatment
Study: 7910871
Drug: drugs and
Normalized name: Prostaglandin analogues, antiglaucoma drugs and miotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: drugs and acupuncture
Study: 26170126
Drug: Aveeno® lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aveeno® lotion
Study: 26170126
Drug: Diprobase® cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diprobase® cream
Study: 26170126
Drug: Doublebase® gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doublebase® gel
Study: 16801838
Drug: Generic prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic prednisolone (15 mg/5 ml)
Study: 16801838
Drug: Orapred (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orapred (15 mg/5 ml)
Study: 12970289
Drug: Oral calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcitriol and calcium
Study: 10656170
Drug: gemfibrozil (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemfibrozil (600 mg bid)
Study: 8683863
Drug: Interleukin-3 (IL-3)
Normalized name: interleukin-3
DrugBank: Muplestim (DB12431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-3 (IL-3) therapy with co-administration of granulocyte colony-stimulating factor (G-CSF) and/or erythropoietin (Epo)
Study: 8683863
Drug: Interleukin-3 (IL-3)
Normalized name: interleukin-3
DrugBank: Muplestim (DB12431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-3 (IL-3) therapy with sequential administration of G-CSF and Epo two weeks after IL-3
Study: 8683863
Drug: Interleukin-3 (IL-3)
Normalized name: interleukin-3
DrugBank: Muplestim (DB12431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-3 (IL-3) therapy
Study: 1861931
Drug: Albuterol syrup
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol syrup (2 mg)
Study: 1861931
Drug: Metaproterenol syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaproterenol syrup (10 mg)
Study: 6409599
Drug: Cinromide (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinromide (1,200 to 4,800 mg/day)
Study: 27123570
Drug: BCG vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccination 0.05 ml intradermally in the upper left arm within seven days of birth
Study: 24725468
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (no incentive)
Study: 18523846
Drug: Ultrasound-guided corticosteroid
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided corticosteroid injection (A1)
Study: 18523846
Drug: Ultrasound-guided extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided extracorporeal shock wave therapy (A2)
Study: 18523846
Drug: Ultrasound-guided corticosteroid
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided corticosteroid injection (B1)
Study: 18523846
Drug: Ultrasound-guided extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided extracorporeal shock wave therapy (B2)
Study: 15867200
Drug: FU/LV/bevacizumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: FU/LV/bevacizumab (5 mg/kg once every 2 weeks)
Study: 30451307
Drug: Abatacept treatment
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept treatment for 6 months
Study: 11838000
Drug: 1.5 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/d n-3 fatty acids
Study: 9543078
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (200 microg/daily)
Study: 3289830
Drug: naproxen CR
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen CR 1000 mg
Study: 4557308
Drug: Carbenoxolone sodium
Normalized name: carbenoxolone sodium
DrugBank: Carbenoxolone (DB02329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone sodium 300 mg daily
Study: 25129247
Drug: Dexketoprofen trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen trometamol (DT) 12.5 mg
Study: 14749544
Drug: Bioequivalence assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioequivalence assessment of prednisone formulations
Study: 11413083
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (NTG) - 4-hour intravenous infusion
Study: 3518528
Drug: Enprofylline (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprofylline (1.0 mg/kg)
Study: 3518528
Drug: Theophylline (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (3.0 mg/kg)
Study: 31952923
Drug: rVSVN4CT1-EBOVGP1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rVSVN4CT1-EBOVGP1 vaccine (high-dose cohort)
Study: 29951651
Drug: NC containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NC containing red yeast rice, policosanols, resveratrol and chromium picolinate (10 mg of monacolin K)
Study: 24831577
Drug: High-dose rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rosuvastatin (40 mg before treatment plus maintenance for 7 days)